Oric Pharmaceuticals Inc ((ORIC)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oric Pharmaceuticals Inc. is conducting a Phase 1b study titled ‘Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC.’ The study aims to determine the recommended phase 2 dose, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ORIC-114 combined with amivantamab in patients with advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
The study tests the combination of ORIC-114, an oral drug, and amivantamab, administered subcutaneously. This combination is intended to target and treat specific genetic mutations in NSCLC patients.
The study is interventional, non-randomized, and follows a sequential model with a 3+3 dose escalation design, proceeding to dose expansion. There is no masking involved, and the primary purpose is treatment.
The study began on February 3, 2025, with the latest update on March 17, 2025. These dates are crucial as they mark the study’s progress and updates, indicating active recruitment and ongoing research.
This clinical study update could influence Oric Pharmaceuticals’ stock performance positively, as successful results may enhance investor confidence. The involvement of Janssen Research and Development LLC as a collaborator adds credibility and potential competitive advantage in the oncology market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.